Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025)
Candel Therapeutics (CADL) posted Return on Capital Employed of 48.07% for Q4 2025, down 5.07% sequentially from 45.75% in Q3 2025, and up 7709.0% YoY from 0.62% in Q4 2024.
Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025) Analysis & Trends
Candel Therapeutics has reported Return on Capital Employed for 5 years, with the latest figure at 48.07% in Q4 2025.
- Quarterly Return on Capital Employed rose 7709.0% year-over-year to 48.07% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 48.07% (up 7709.0% YoY) and the FY2025 annual result came in at 45.09%, up 4632.0% from the prior year.
- Return on Capital Employed slipped to 48.07% in Q4 2025 per CADL's latest filing, from 45.75% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 29.5% in Q4 2021 and troughed at 407.05% in Q3 2024.
- A 5-year average of 92.3% and a median of 46.96% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 32495 bps in 2024, then surged 36130 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 29.5% in 2021, then sank by 55 bps to 45.85% in 2022, then tumbled by 166 bps to 122.08% in 2023, then slipped by 3 bps to 125.16% in 2024, then jumped by 62 bps to 48.07% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 48.07%, 45.75%, and 41.99% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -48.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -48.07% |
| Sep 30, 2025 | -45.75% |
| Jun 30, 2025 | -41.99% |
| Mar 31, 2025 | -41.32% |
| Dec 31, 2024 | -125.16% |
| Sep 30, 2024 | -407.05% |
| Jun 30, 2024 | -240.00% |
| Mar 31, 2024 | -161.70% |
| Dec 31, 2023 | -122.08% |
| Sep 30, 2023 | -82.11% |
| Jun 30, 2023 | -66.04% |
| Mar 31, 2023 | -52.61% |
| Dec 31, 2022 | -45.85% |
| Sep 30, 2022 | -41.27% |
| Jun 30, 2022 | -36.60% |
| Mar 31, 2022 | -33.43% |
| Dec 31, 2021 | -29.50% |
| Sep 30, 2021 | -40.90% |